Evaluating new methods for estimating the hypothetical estimand on overall survival in the presence of different effective subsequent therapies - a simulation study with application to a clinical trial

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Statistics in Biopharmaceutical Research

• Publication date

  2025-11-10

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1080/19466315.2025.2579552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone

  2024cited by this paper
• On estimation for accelerated failure time models with small or rare event survival data

  2022cited by this paper
• An introduction to inverse probability of treatment weighting in observational research

  2021cited by this paper
• Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials

  2021cited by this paper
• Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study

  2021cited by this paper
• Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2021cited by this paper
• Simulating Survival Data Using the simsurv R Package

  2021cited by this paper
• Estimands for overall survival in clinical trials with treatment switching in oncology

  2021cited by this paper
• Using marginal structural models to analyze the impact of subsequent therapy on the treatment effect in survival data: Simulations and clinical trial examples

  2021cited by this paper
• Prediction meets causal inference: the role of treatment in clinical prediction models

  2020cited by this paper
• SURVIVAL ANALYSIS

  2020cited by this paper
• ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.

  2020cited by this paper
• Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding

  2020cited by this paper
• Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring

  2019cited by this paper
• Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

  2019cited by this paper
• PRM233 - THE USE OF THE TWO-STAGE METHOD IN ADJUSTING FOR TREATMENT CROSSOVER. A SIMULATION STUDY.

  2018cited by this paper
• Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method

  2017cited by this paper
• Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer

  2016cited by this paper
• Prognostic Factors in Hodgkin Lymphoma

  2014cited by this paper
• Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation.

  2013cited by this paper
• Adjusting overall survival for treatment switches: commonly used methods and practical application

  2013cited by this paper
• On computing standard errors for marginal structural Cox models

  2013cited by this paper
• ipw: An R Package for Inverse Probability Weighting

  2011cited by this paper
• Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias.

  2011cited by this paper
• Constructing inverse probability weights for marginal structural models.

  2008cited by this paper
• Generating survival times to simulate Cox proportional hazards models

  2005cited by this paper
• Adjusting for differential proportions of second‐line treatment in cancer clinical trials. Part I: Structural nested models and marginal structural models to test and estimate treatment arm effects

  2004cited by this paper
• Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

  2000cited by this paper
• Indicator and stratification methods for missing explanatory variables in multiple linear regression

  1996cited by this paper
• The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis.

  1992cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper

• No citing papers are available for this paper.